Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck
BackgroundImmune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall response rate (ORR) is limited to 10-20%, and subsequent chemotherapy is critical to maximizing the subjects’ prognosis.MethodsW...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1221352/full |
| _version_ | 1797489080175427584 |
|---|---|
| author | Hideki Tanaka Hideki Tanaka Tomohiro Enokida Susumu Okano Takao Fujisawa Nobukazu Tanaka Naohiro Takeshita Naohiro Takeshita Ryutaro Onaga Yuta Hoshi Yuta Hoshi Akihisa Wada Akihisa Wada Masanobu Sato Masanobu Sato Yuri Ueda Yuri Ueda Makoto Tahara |
| author_facet | Hideki Tanaka Hideki Tanaka Tomohiro Enokida Susumu Okano Takao Fujisawa Nobukazu Tanaka Naohiro Takeshita Naohiro Takeshita Ryutaro Onaga Yuta Hoshi Yuta Hoshi Akihisa Wada Akihisa Wada Masanobu Sato Masanobu Sato Yuri Ueda Yuri Ueda Makoto Tahara |
| author_sort | Hideki Tanaka |
| collection | DOAJ |
| description | BackgroundImmune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall response rate (ORR) is limited to 10-20%, and subsequent chemotherapy is critical to maximizing the subjects’ prognosis.MethodsWe retrospectively reviewed 59 patients with R/M SCCHN treated with paclitaxel+cetuximab (PE)-based chemotherapy (PCE, paclitaxel+carboplatin+cetuximab; or PTX+Cmab, paclitaxel+cetuximab) following disease progression after either pembrolizumab or nivolumab monotherapy.ResultsOf 59 patients, 15 were treated with pembrolizumab, with an ORR of 13.3%, and the remaining 44 with nivolumab, with an ORR of 11.4%. All patients in the pembrolizumab cohort had platinum-sensitive disease. Following ICI treatment, 19 patients were treated with PCE and the remaining 40 with PTX+Cmab. PE-based chemotherapy induced favorable and prompt tumor shrinkage even in cases where ICI was not effective, with a median change in the summed dimensions of target lesions of -43.4%, resulting in an ORR of 62.7%. Median time to response was 1.8 months. The patients in the pembrolizumab cohort appeared to have a numerically higher response rate than those receiving nivolumab (80.0% vs. 56.8%). For the 59 patients, progression-free survival and overall survival, calculated from the initiation of PE-based chemotherapy, were 4.6 months and 17.1 months, respectively. Grade ≥3 adverse events occurred in 40.7%, and no treatment-related death was observed.ConclusionPE-based chemotherapy following ICI is encouraging for its robust antitumor efficacy in R/M SCCHN. |
| first_indexed | 2024-03-10T00:11:25Z |
| format | Article |
| id | doaj.art-ba07fb074d6240e3bcd6832f75fe358e |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-10T00:11:25Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ba07fb074d6240e3bcd6832f75fe358e2023-11-23T15:58:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-11-011310.3389/fonc.2023.12213521221352Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neckHideki Tanaka0Hideki Tanaka1Tomohiro Enokida2Susumu Okano3Takao Fujisawa4Nobukazu Tanaka5Naohiro Takeshita6Naohiro Takeshita7Ryutaro Onaga8Yuta Hoshi9Yuta Hoshi10Akihisa Wada11Akihisa Wada12Masanobu Sato13Masanobu Sato14Yuri Ueda15Yuri Ueda16Makoto Tahara17Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Otorhinolaryngology-Head and Neck Surgery, Tokyo Medical University, Tokyo, JapanDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Otorhinolaryngology, Jikei University School of Medicine, Tokyo, JapanDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Head and Neck Surgery, Tokyo Medical and Dental University, Tokyo, JapanDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, JapanDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Otorhinolaryngology-Head and Neck Surgery, Tokyo Medical University, Tokyo, JapanDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, JapanBackgroundImmune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall response rate (ORR) is limited to 10-20%, and subsequent chemotherapy is critical to maximizing the subjects’ prognosis.MethodsWe retrospectively reviewed 59 patients with R/M SCCHN treated with paclitaxel+cetuximab (PE)-based chemotherapy (PCE, paclitaxel+carboplatin+cetuximab; or PTX+Cmab, paclitaxel+cetuximab) following disease progression after either pembrolizumab or nivolumab monotherapy.ResultsOf 59 patients, 15 were treated with pembrolizumab, with an ORR of 13.3%, and the remaining 44 with nivolumab, with an ORR of 11.4%. All patients in the pembrolizumab cohort had platinum-sensitive disease. Following ICI treatment, 19 patients were treated with PCE and the remaining 40 with PTX+Cmab. PE-based chemotherapy induced favorable and prompt tumor shrinkage even in cases where ICI was not effective, with a median change in the summed dimensions of target lesions of -43.4%, resulting in an ORR of 62.7%. Median time to response was 1.8 months. The patients in the pembrolizumab cohort appeared to have a numerically higher response rate than those receiving nivolumab (80.0% vs. 56.8%). For the 59 patients, progression-free survival and overall survival, calculated from the initiation of PE-based chemotherapy, were 4.6 months and 17.1 months, respectively. Grade ≥3 adverse events occurred in 40.7%, and no treatment-related death was observed.ConclusionPE-based chemotherapy following ICI is encouraging for its robust antitumor efficacy in R/M SCCHN.https://www.frontiersin.org/articles/10.3389/fonc.2023.1221352/fullpembrolizumabsubsequent chemotherapypaclitaxelcetuximabcarboplatinrecurrent/metastasis squamous cell carcinoma of the head and neck |
| spellingShingle | Hideki Tanaka Hideki Tanaka Tomohiro Enokida Susumu Okano Takao Fujisawa Nobukazu Tanaka Naohiro Takeshita Naohiro Takeshita Ryutaro Onaga Yuta Hoshi Yuta Hoshi Akihisa Wada Akihisa Wada Masanobu Sato Masanobu Sato Yuri Ueda Yuri Ueda Makoto Tahara Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck Frontiers in Oncology pembrolizumab subsequent chemotherapy paclitaxel cetuximab carboplatin recurrent/metastasis squamous cell carcinoma of the head and neck |
| title | Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck |
| title_full | Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck |
| title_fullStr | Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck |
| title_full_unstemmed | Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck |
| title_short | Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck |
| title_sort | subsequent chemotherapy with paclitaxel plus cetuximab based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck |
| topic | pembrolizumab subsequent chemotherapy paclitaxel cetuximab carboplatin recurrent/metastasis squamous cell carcinoma of the head and neck |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1221352/full |
| work_keys_str_mv | AT hidekitanaka subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT hidekitanaka subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT tomohiroenokida subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT susumuokano subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT takaofujisawa subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT nobukazutanaka subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT naohirotakeshita subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT naohirotakeshita subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT ryutaroonaga subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT yutahoshi subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT yutahoshi subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT akihisawada subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT akihisawada subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT masanobusato subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT masanobusato subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT yuriueda subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT yuriueda subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck AT makototahara subsequentchemotherapywithpaclitaxelpluscetuximabbasedchemotherapyfollowingimmunecheckpointinhibitorinrecurrentormetastaticsquamouscellcarcinomaoftheheadandneck |